Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.

Kumar, Rahul; Aktay-Cetin, Öznur; Craddock, Vaughn; Morales-Cano, Daniel; Kosanovic, Djuro; Cogolludo, Angel; Perez-Vizcaino, Francisco; Avdeev, Sergey; Kumar, Ashok; Ram, Anil Kumar; Agarwal, Stuti; Chakraborty, Ananya; Savai, Rajkumar; de Jesus Perez, Vinicio; Graham, Brian B; Butrous, Ghazwan; Dhillon, Navneet K

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.

The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapie...

Descripción completa

Detalles Bibliográficos
Autores:	Kumar, Rahul, Aktay-Cetin, Öznur, Craddock, Vaughn, Morales-Cano, Daniel, Kosanovic, Djuro, Cogolludo, Angel, Perez-Vizcaino, Francisco, Avdeev, Sergey, Kumar, Ashok, Ram, Anil Kumar, Agarwal, Stuti, Chakraborty, Ananya, Savai, Rajkumar, de Jesus Perez, Vinicio, Graham, Brian B, Butrous, Ghazwan, Dhillon, Navneet K
Tipo de recurso:	artículo
Fecha de publicación:	2023
País:	España
Institución:	Instituto de Salud Carlos III (ISCIII)
Repositorio:	Repisalud
Idioma:	inglés
OAI Identifier:	oai:repisalud.isciii.es:20.500.12105/16637
Acceso en línea:	http://hdl.handle.net/20.500.12105/16637
Access Level:	acceso abierto
Palabra clave:	COVID-19 Coinfection Humans SARS-CoV-2 Lung Cross Reactions

id	ES_bef77d2a05cc7f482efe8efa76a0f418
oai_identifier_str	oai:repisalud.isciii.es:20.500.12105/16637
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.Kumar, RahulAktay-Cetin, ÖznurCraddock, VaughnMorales-Cano, DanielKosanovic, DjuroCogolludo, AngelPerez-Vizcaino, FranciscoAvdeev, SergeyKumar, AshokRam, Anil KumarAgarwal, StutiChakraborty, AnanyaSavai, Rajkumarde Jesus Perez, VinicioGraham, Brian BButrous, GhazwanDhillon, Navneet KCOVID-19CoinfectionHumansSARS-CoV-2LungCross ReactionsThe Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapies. COVID-19, although targeting primarily the respiratory system, is also now well established that later affects every organ in the body. Most importantly, despite the available therapy and vaccine-elicited protection, the long-term consequences of viral infection in breakthrough and asymptomatic individuals are areas of concern. In the past two years, investigators accumulated evidence on how the virus triggers our immune system and the molecular signals involved in the cross-talk between immune cells and structural cells in the pulmonary vasculature to drive pathological lung complications such as endothelial dysfunction and thrombosis. In the review, we emphasize recent updates on the pathophysiological inflammatory and immune responses associated with SARS-CoV-2 infection and their potential long-term consequences that may consequently lead to the development of pulmonary vascular diseases.Public Library of Science (PLOS)American Heart AssociationMinisterio de Ciencia e Innovación (España)20232023-11-0620232023-01-0120232023-01-01journal articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/20.500.12105/16637reponame:Repisaludinstname:Instituto de Salud Carlos III (ISCIII)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Atribución 4.0 Internacionalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repisalud.isciii.es:20.500.12105/166372026-06-12T12:43:37Z
dc.title.none.fl_str_mv	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
title	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
spellingShingle	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities. Kumar, Rahul COVID-19 Coinfection Humans SARS-CoV-2 Lung Cross Reactions
title_short	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
title_full	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
title_fullStr	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
title_full_unstemmed	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
title_sort	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.
dc.creator.none.fl_str_mv	Kumar, Rahul Aktay-Cetin, Öznur Craddock, Vaughn Morales-Cano, Daniel Kosanovic, Djuro Cogolludo, Angel Perez-Vizcaino, Francisco Avdeev, Sergey Kumar, Ashok Ram, Anil Kumar Agarwal, Stuti Chakraborty, Ananya Savai, Rajkumar de Jesus Perez, Vinicio Graham, Brian B Butrous, Ghazwan Dhillon, Navneet K
author	Kumar, Rahul
author_facet	Kumar, Rahul Aktay-Cetin, Öznur Craddock, Vaughn Morales-Cano, Daniel Kosanovic, Djuro Cogolludo, Angel Perez-Vizcaino, Francisco Avdeev, Sergey Kumar, Ashok Ram, Anil Kumar Agarwal, Stuti Chakraborty, Ananya Savai, Rajkumar de Jesus Perez, Vinicio Graham, Brian B Butrous, Ghazwan Dhillon, Navneet K
author_role	author
author2	Aktay-Cetin, Öznur Craddock, Vaughn Morales-Cano, Daniel Kosanovic, Djuro Cogolludo, Angel Perez-Vizcaino, Francisco Avdeev, Sergey Kumar, Ashok Ram, Anil Kumar Agarwal, Stuti Chakraborty, Ananya Savai, Rajkumar de Jesus Perez, Vinicio Graham, Brian B Butrous, Ghazwan Dhillon, Navneet K
author2_role	author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	American Heart Association Ministerio de Ciencia e Innovación (España)
dc.subject.none.fl_str_mv	COVID-19 Coinfection Humans SARS-CoV-2 Lung Cross Reactions
topic	COVID-19 Coinfection Humans SARS-CoV-2 Lung Cross Reactions
description	The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its sublineages pose a new challenge to healthcare systems worldwide due to its ability to efficiently spread in immunized populations and its resistance to currently available therapies. COVID-19, although targeting primarily the respiratory system, is also now well established that later affects every organ in the body. Most importantly, despite the available therapy and vaccine-elicited protection, the long-term consequences of viral infection in breakthrough and asymptomatic individuals are areas of concern. In the past two years, investigators accumulated evidence on how the virus triggers our immune system and the molecular signals involved in the cross-talk between immune cells and structural cells in the pulmonary vasculature to drive pathological lung complications such as endothelial dysfunction and thrombosis. In the review, we emphasize recent updates on the pathophysiological inflammatory and immune responses associated with SARS-CoV-2 infection and their potential long-term consequences that may consequently lead to the development of pulmonary vascular diseases.
publishDate	2023
dc.date.none.fl_str_mv	2023 2023-11-06 2023 2023-01-01 2023 2023-01-01
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501 VoR http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	http://hdl.handle.net/20.500.12105/16637
url	http://hdl.handle.net/20.500.12105/16637
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Public Library of Science (PLOS)
publisher.none.fl_str_mv	Public Library of Science (PLOS)
dc.source.none.fl_str_mv	reponame:Repisalud instname:Instituto de Salud Carlos III (ISCIII)
instname_str	Instituto de Salud Carlos III (ISCIII)
reponame_str	Repisalud
collection	Repisalud
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869418329419022336
score	15,812429

Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: Multilayered cross-talks in the setting of coinfections and comorbidities.

Similares en LA Referencia